Study guide
5.2 Clinical Assessment, Diagnostic Imaging & BI-RADS Categorization
CBCN Certified Breast Care Nurse Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CBCN Exam
CBCN Exam Facts, 2026 Blueprint & Study Plan
2 Chapter 1: Breast Health, Examination & Benign Conditions (Care Continuum)
1.1 Breast Anatomy, Vascular Supply & Hormonal Physiology 1.2 Clinical Breast Examination & Breast Awareness Education 1.3 Benign Breast Conditions, Mastalgia & Fibrocystic Changes
3 Chapter 2: Screening, Breast Density & Special Populations (Care Continuum)
2.1 Screening Modalities, Breast Density & Pharmacologic Risk Reduction 2.2 Screening & Breast Health in Special Populations
4 Chapter 3: Cancer Risk Assessment & Genetics (Care Continuum)
3.1 Proliferative Lesions, Atypia & High-Risk Benign Pathology 3.2 Breast Cancer Risk Models (Gail, Tyrer-Cuzick, Claus, BRCAPRO) 3.3 Hereditary Cancer Syndromes & Genetic Evaluation
5 Chapter 4: Patient Navigation, Surveillance & Survivorship (Care Continuum)
4.1 Patient Navigation, Barriers to Care, Social Determinants & Interprofessional Collaboration 4.2 Survivorship Care Planning, Surveillance Intervals & Recurrence Monitoring 4.3 Secondary Prevention, Physical Activity, Nutrition & Wellness Guidance
6 Chapter 5: Carcinogenesis & Diagnostic Evaluation (Diagnosis and Staging)
5.1 Carcinogenesis: How Breast Cancer Develops and Spreads 5.2 Clinical Assessment, Diagnostic Imaging & BI-RADS Categorization 5.3 Breast Biopsy Modalities & Image-Guided Localization Techniques
7 Chapter 6: Pathology, Biomarkers & Genomic Testing (Diagnosis and Staging)
6.1 Histopathology: In Situ Carcinomas & Invasive Carcinoma Subtypes 6.2 Receptor Biomarkers (ER, PR, HER2, Ki-67) & Molecular Subtypes 6.3 Multigene Genomic Assays & Recurrence Risk Stratification
8 Chapter 7: Clinical & Pathologic Staging (Diagnosis and Staging)
7.1 AJCC TNM Staging System (Anatomic vs Prognostic Staging) 7.2 Staging Workup: When to Use MRI, CT, Bone Scan & PET
9 Chapter 8: Breast Surgery, Axillary Staging & Reconstruction (Treatment Modalities)
8.1 Breast-Conserving Surgery, Margin Standards & Mastectomy Techniques 8.2 Axillary Staging: Sentinel Lymph Node Biopsy vs. Axillary Dissection 8.3 Post-Mastectomy Reconstruction & Oncoplastic Surgery
10 Chapter 9: Radiation Therapy & Chemotherapy (Treatment Modalities)
9.1 Radiation Therapy: Whole Breast, Chest Wall, Regional Nodal & Partial Breast Irradiation 9.2 Neoadjuvant vs. Adjuvant Chemotherapy Principles & Standard Regimens
11 Chapter 10: Endocrine, HER2-Targeted & Novel Systemic Therapies (Treatment Modalities)
10.1 Endocrine Therapy: SERMs, Aromatase Inhibitors, Ovarian Suppression & SERDs 10.2 HER2-Targeted Monoclonal Antibodies, Antibody-Drug Conjugates & Kinase Inhibitors 10.3 CDK4/6 Inhibitors, PARP Inhibitors & Immune Checkpoint Blockade 10.4 Trop-2 Antibody-Drug Conjugates, PI3K/AKT/mTOR Inhibitors & New Oral SERDs
12 Chapter 11: Specific Conditions & Special Populations (Treatment Modalities)
11.1 Triple-Negative Breast Cancer: Treatment Considerations 11.2 HER2-Positive Breast Cancer: Treatment Considerations 11.3 Inflammatory Breast Cancer & Paget Disease of the Nipple 11.4 Phyllodes Tumors & Breast Angiosarcoma 11.5 Treatment Considerations for Special Populations
13 Chapter 12: Symptom Management & Supportive Care (Nursing Practice)
12.1 Acute Chemotherapy Toxicities, Supportive Regimens & Oncologic Emergencies 12.2 Lymphedema Pathophysiology, ISL Staging & Complete Decongestive Therapy (CDT) 12.3 Musculoskeletal Toxicities, Bone Health & Vasomotor/GSM Relief 12.4 Complementary & Integrative Modalities 12.5 Cancer Rehabilitation: Physical, Occupational & Pelvic Floor Therapy
14 Chapter 13: Oncologic Emergencies (Nursing Practice)
13.1 Oncologic Emergencies I: Spinal Cord Compression, Hypercalcemia, Tamponade & SVC Syndrome 13.2 Oncologic Emergencies II: Hypersensitivity & Anaphylaxis, Sepsis, Pleural Effusion & Thromboembolism
15 Chapter 14: Professional Practice, Clinical Trials & Self-Care (Nursing Practice)
14.1 Professional Practice: Guidelines, Ethics, Legislation, Outreach & Accreditation 14.2 Clinical Trials in Breast Oncology 14.3 Nurse Self-Care: Compassion Fatigue, Burnout, Moral Distress & Substance Use
16 Chapter 15: Psychosocial Dimensions of Care (Psychosocial Dimensions)
15.1 Psychosocial Distress, Coping, Grief & Palliative Care 15.2 Culture, Spirituality, Sexual & Gender Identity, Age & Healthcare Disparities 15.3 Family & Caregiver Dynamics 15.4 Altered Body Image 15.5 Reproductive & Sexual Health
5.2 Clinical Assessment, Diagnostic Imaging & BI-RADS Categorization
Key Takeaways Explain This Topic AI
Pathologic nipple discharge is characteristically unilateral, spontaneous, persistent, from a single duct orifice, and serous or bloody, requiring diagnostic imaging and surgical evaluation.
Diagnostic mammography utilizes tailored spot compression and magnification views to resolve palpable lumps, focal asymmetries, and microcalcification morphology.
Diagnostic breast ultrasound differentiates solid from cystic lesions and identifies malignant sonographic features such as taller-than-wide orientation, hypoechogenicity, and spiculated margins.
Contrast-enhanced breast MRI provides superior sensitivity (90-95%) for evaluating occult primaries presenting with axillary metastases, extent of invasive lobular carcinoma, and silicone implant integrity.
The ACR BI-RADS system standardizes risk assessment from Category 0 (incomplete) through Category 6 (biopsy-proven malignancy), directing management from short-interval surveillance (Category 3, 2% or lower risk) to mandatory tissue biopsy (Categories 4 and 5).
Last updated: September 2026
Clinical breast assessment begins with a focused health history and thorough physical examination to differentiate physiologic variations from suspicious symptoms requiring urgent diagnostic workup. Breast care nurses play a pivotal role in triaging patient symptoms, coordinating multi-modality diagnostic imaging, and explaining complex radiologic findings to alleviate distress.
Clinical Evaluation of Breast Symptoms
Patients presenting with breast complaints require systematic evaluation of palpable masses, skin changes, nipple alterations, and discharge patterns.
Palpable Breast Masses
A palpable breast mass is the most common presenting symptom of breast disease. Clinical examination evaluates mass size, shape, consistency, mobility, and relationship to surrounding anatomic structures:
Malignant features : Classically solitary, firm-to-hard, painless, poorly circumscribed with irregular margins, and fixed or tethered to underlying pectoral fascia or overlying skin.
Benign features : Typically smooth, round or ovoid, soft to rubbery/elastic, well-demarcated, mobile, and frequently tender or fluctuating in size with the menstrual cycle (e.g., simple cysts, fibroadenomas).
Clinical pearl : Any newly discovered, persistent, dominant solid mass requires diagnostic imaging and tissue sampling regardless of patient age or reassuring physical exam findings, as up to 10% to 15% of breast malignancies are mammographically occult.
Nipple and Areolar Changes
Nipple alterations provide critical clues regarding retroareolar pathology:
Nipple retraction and inversion : Longstanding congenital nipple inversion is typically bilateral and easily everted with gentle manipulation. In contrast, newly acquired, fixed unilateral nipple retraction or slit-like deviation signifies underlying parenchymal fibrosis or an invasive tumor pulling on retroareolar lactiferous ducts.
Scaling, crusting, and eczematoid ulceration : Unilateral scaling, persistent erythema, and weeping ulceration of the nipple-areolar complex are classical signs of Paget disease of the nipple. Often misdiagnosed as contact dermatitis or eczema, this condition represents malignant adenocarcinoma cells within the epidermis and is associated with an underlying in situ or invasive malignancy in over 90% of cases.
Skin Changes
Cutaneous manifestations reflect tumor infiltration into superficial lymphatic channels or structural fascial ligaments:
Skin tethering and dimpling : Desmoplastic stromal reaction surrounding a carcinoma shortens the suspensory retinacula cutis (Cooper's ligaments), resulting in focal skin retraction visible when the patient raises their arms overhead or contracts the pectoralis major muscles.
Erythema and peau d'orange : Diffuse erythema, cutaneous warmth, and marked dermal edema with exaggerated follicular openings (peau d'orange, resembling orange peel skin) signal obstruction of dermal lymphatic drainage by tumor emboli, the hallmark presentation of inflammatory breast cancer (IBC).
Pathologic vs. Physiologic Nipple Discharge
Nipple discharge accounts for approximately 5% to 7% of outpatient breast referrals. Differentiating benign physiologic secretion from pathologic discharge is essential:
Pathologic discharge : Unilateral, spontaneous (discharging without external manipulation), persistent, issuing from a solitary duct orifice, and serous, serosanguinous, or frank bloody in appearance. The most frequent cause is a benign solitary intraductal papilloma (50% to 70%), followed by duct ectasia, but underlying ductal carcinoma in situ (DCIS) or invasive carcinoma is identified in 5% to 15% of cases.
Physiologic discharge : Bilateral, non-spontaneous (elicited only with vigorous manual expression or breast pumping), multi-ductal, and variable in color (milky white, dark green, brownish, or amber). Milky discharge (galactorrhea) stems from hyperprolactinemia, thyroid dysfunction, medications (e.g., antipsychotics, metoclopramide), or chronic chest wall stimulation.
Diagnostic Imaging Modalities
When a clinical abnormality is identified or a screening exam yields an abnormal finding, diagnostic imaging is performed under the direct supervision of a dedicated breast radiologist.
Diagnostic Mammography vs. Screening Mammography
Screening mammography consists of standard bilateral two-view examinations—craniocaudal (CC) and mediolateral oblique (MLO)—performed on asymptomatic individuals. In contrast, diagnostic mammography is tailored to investigate specific signs, symptoms, or screening recalls:
Spot compression views : Direct focal pressure over an area of concern to displace overlapping glandular parenchyma, determining whether an apparent density represents superimposition or a true three-dimensional parenchymal mass or architectural distortion.
Magnification views : Performed without a grid using a small focal spot to magnify microcalcifications, allowing precise assessment of their morphology (fine pleomorphic, amorphous, fine linear branching) and spatial distribution (grouped, linear, segmental).
Tangential views : Profile cutaneous moles, scars, or superficial lesions using radiopaque skin markers to confirm their dermal origin and avoid unnecessary biopsies.
Diagnostic Breast Ultrasound
High-resolution diagnostic ultrasound (using high-frequency linear-array transducers of 12 to 18 MHz) is the initial imaging modality of choice for women under age 30, pregnant or lactating individuals, and as an essential adjunct to mammography for characterization of palpable or mammographically detected abnormalities:
Cystic vs. solid distinction : Readily distinguishes simple cysts (anechoic, round or oval, smooth thin margins, posterior acoustic enhancement; 0% malignancy risk) from complex cystic and solid masses (thick walls, internal septations, intracystic solid components) and solid lesions.
Malignant sonographic features : Hypoechoic parenchyma, taller-than-wide orientation (anteroposterior dimension exceeding transverse dimension, indicating growth cutting across normal tissue planes), irregular or spiculated margins, angular or microlobulated contours, marked posterior acoustic shadowing, and internal microvascularity on color Doppler.
Benign sonographic features : Well-circumscribed margins, oval or round shape, wider-than-tall orientation (parallel to skin), uniform hyperechogenicity, and bilateral edge refraction shadowing.
Diagnostic Breast Magnetic Resonance Imaging (MRI)
Dynamic contrast-enhanced breast MRI with intravenous gadolinium chelate offers high diagnostic sensitivity (exceeding 90% to 95%) by demonstrating tumor-induced neoangiogenesis, characterized by rapid arterial wash-in and delayed wash-out kinetics. Common clinical indications include:
Occult primary breast carcinoma : Investigating patients presenting with biopsy-proven metastatic adenocarcinoma in axillary lymph nodes when clinical exam, mammography, and ultrasound fail to identify a primary breast tumor (TxN+ disease).
Extent of disease assessment : Evaluating multifocal, multicentric, or contralateral disease in patients with newly diagnosed invasive lobular carcinoma (ILC), which has a notorious propensity for subtle, diffuse, mammographically occult infiltration.
Neoadjuvant therapy monitoring : Assessing residual tumor volume and biologic response during and following neoadjuvant systemic therapy to plan breast-conserving surgery.
Silicone implant integrity : Evaluating suspected intra-capsular rupture (characterized by the "linguine sign" on non-contrast T2-weighted sequences) or extra-capsular silicone extravasation.
The ACR BI-RADS Categorization System
The American College of Radiology (ACR) Breast Imaging Reporting and Data System (BI-RADS) establishes a standardized lexicon and structured assessment categories to guide clinical management.
BI-RADS Category Assessment Classification Malignancy Likelihood Typical Imaging Features Clinical Management Action
Category 0 Incomplete Assessment Undetermined Technical defect, dense obscuring tissue, non-evaluated asymmetry Additional imaging views (spot compression, magnification), ultrasound, or retrieval of prior comparison exams
Category 1 Negative 0% Symmetrical parenchyma, no masses, suspicious calcifications, or distortions Routine screening interval appropriate for age and risk profile
Category 2 Benign Finding 0% Simple breast cyst, stable calcified fibroadenoma, secretory calcifications, fat necrosis, intramammary lymph node Routine screening interval; benign findings documented for baseline stability
Category 3 Probably Benign Greater than 0% to 2% or less Non-palpable circumscribed oval solid mass, focal asymmetry without distortion, round punctate calcification cluster Short-interval unilateral surveillance imaging at 6, 12, and 24 months to document 2-year stability
Category 4A Low Suspicion for Malignancy Greater than 2% to 10% or less Partially circumscribed mass with sonographic features of atypical cyst, subcentimeter focal asymmetry Image-guided percutaneous core needle biopsy
Category 4B Moderate Suspicion for Malignancy Greater than 10% to 50% or less Amorphous or coarse heterogeneous microcalcifications, solid mass with indistinct microlobulated margins Image-guided percutaneous core needle biopsy with clip placement
Category 4C High Suspicion for Malignancy Greater than 50% to less than 95% Fine pleomorphic calcifications, new irregular solid mass with indistinct margins Image-guided percutaneous core needle biopsy; prompt pathology review and surgical consultation
Category 5 Highly Suggestive of Malignancy 95% or greater Spiculated irregular dense mass, fine linear branching microcalcifications in segmental distribution Prompt image-guided core biopsy; multi-disciplinary breast oncology referral for staging and definitive treatment
Category 6 Known Biopsy-Proven Malignancy 100% Established invasive carcinoma or DCIS on histology Imaging obtained for surgical excision planning, staging, or monitoring neoadjuvant therapy response
Nursing Considerations in Diagnostic Assessment
Breast care nurses support patients through the vulnerable diagnostic evaluation window by:
Alleviating diagnostic anxiety : Reassuring patients that a recall from screening mammography (BI-RADS 0) occurs in approximately 8% to 12% of screening exams and that the vast majority (greater than 90%) result in benign outcomes.
Patient education : Clarifying the rationale for short-interval imaging in BI-RADS 3 findings versus the necessity of histological sampling for BI-RADS 4 or 5 lesions.
Care coordination : Ensuring rapid turnaround times between abnormal imaging and biopsy, and facilitating navigation to genetic counselors, surgical oncologists, and support resources.